Global Nonspecific Universal Nuclease Market Growth (Status and Outlook) 2025-2031
Description
The global Nonspecific Universal Nuclease market size is predicted to grow from US$ 88 million in 2025 to US$ 186 million in 2031; it is expected to grow at a CAGR of 13.3% from 2025 to 2031.
Nonspecific universal nuclease, a genetically engineered enzyme derived from Serratia marcescens. It can degrade all forms of DNA and RNA, including single-stranded, double-stranded, linear, circular, native and denatured nucleic acids, and digest them into 5-monophosphate oligonucleotides of 3-8 bases in length, without base recognition specificity. In addition, nonspecific universal nuclease can maintain high stability and digestive activity under a wide range of conditions (6M urea, 0.1M guanidine hydrochloride, 0.4% Triton X100, 0.1% SDS, 1mM EDTA, 1mM PMSF), and is very suitable as the preferred enzyme preparation for various scientific research and vaccine, protein, and polysaccharide drug industries, used to remove nucleic acid residues in samples or products, and improve sample purity and product biological efficacy.
United States market for Nonspecific Universal Nuclease is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Nonspecific Universal Nuclease is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Nonspecific Universal Nuclease is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Nonspecific Universal Nuclease players cover Thermo Fisher Scientific Inc., RayBiotech, TransGen Biotech, Yeasen, GenScript, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Nonspecific Universal Nuclease Industry Forecast” looks at past sales and reviews total world Nonspecific Universal Nuclease sales in 2024, providing a comprehensive analysis by region and market sector of projected Nonspecific Universal Nuclease sales for 2025 through 2031. With Nonspecific Universal Nuclease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nonspecific Universal Nuclease industry.
This Insight Report provides a comprehensive analysis of the global Nonspecific Universal Nuclease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Nonspecific Universal Nuclease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nonspecific Universal Nuclease market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nonspecific Universal Nuclease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nonspecific Universal Nuclease.
This report presents a comprehensive overview, market shares, and growth opportunities of Nonspecific Universal Nuclease market by product type, application, key players and key regions and countries.
Segmentation by Type:
Purity ＞ 95%
Purity ≤ 95%
Segmentation by Application:
Medical and Biological Laboratories
University Research Room
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific Inc.
RayBiotech
TransGen Biotech
Yeasen
GenScript
Beyotime
KACTUS
ACROBiosystems
Merck
ProSpec
Gproan
Bio-Techne Corporation
AMSBIO
Enzynomics
ProteoGenix
Vazyme
Sino Biological
Novoprotein
New England Biolabs
Please note: The report will take approximately 2 business days to prepare and deliver.
Nonspecific universal nuclease, a genetically engineered enzyme derived from Serratia marcescens. It can degrade all forms of DNA and RNA, including single-stranded, double-stranded, linear, circular, native and denatured nucleic acids, and digest them into 5-monophosphate oligonucleotides of 3-8 bases in length, without base recognition specificity. In addition, nonspecific universal nuclease can maintain high stability and digestive activity under a wide range of conditions (6M urea, 0.1M guanidine hydrochloride, 0.4% Triton X100, 0.1% SDS, 1mM EDTA, 1mM PMSF), and is very suitable as the preferred enzyme preparation for various scientific research and vaccine, protein, and polysaccharide drug industries, used to remove nucleic acid residues in samples or products, and improve sample purity and product biological efficacy.
United States market for Nonspecific Universal Nuclease is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Nonspecific Universal Nuclease is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Nonspecific Universal Nuclease is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Nonspecific Universal Nuclease players cover Thermo Fisher Scientific Inc., RayBiotech, TransGen Biotech, Yeasen, GenScript, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Nonspecific Universal Nuclease Industry Forecast” looks at past sales and reviews total world Nonspecific Universal Nuclease sales in 2024, providing a comprehensive analysis by region and market sector of projected Nonspecific Universal Nuclease sales for 2025 through 2031. With Nonspecific Universal Nuclease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nonspecific Universal Nuclease industry.
This Insight Report provides a comprehensive analysis of the global Nonspecific Universal Nuclease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Nonspecific Universal Nuclease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nonspecific Universal Nuclease market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nonspecific Universal Nuclease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nonspecific Universal Nuclease.
This report presents a comprehensive overview, market shares, and growth opportunities of Nonspecific Universal Nuclease market by product type, application, key players and key regions and countries.
Segmentation by Type:
Purity ＞ 95%
Purity ≤ 95%
Segmentation by Application:
Medical and Biological Laboratories
University Research Room
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific Inc.
RayBiotech
TransGen Biotech
Yeasen
GenScript
Beyotime
KACTUS
ACROBiosystems
Merck
ProSpec
Gproan
Bio-Techne Corporation
AMSBIO
Enzynomics
ProteoGenix
Vazyme
Sino Biological
Novoprotein
New England Biolabs
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
139 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Nonspecific Universal Nuclease Market Size by Player
- 4 Nonspecific Universal Nuclease by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Nonspecific Universal Nuclease Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
